Chen Feng, Jiang Jun, Tian Dan-Dan, Wen Qi, Li Yong-Hui, Zhang Jun-Qing, Cheng Chen, Wang Tengfei
Hainan Provincial Key Laboratory of R&D of Tropical Herbs, School of Pharmacy, Hainan Medical College, Haikou. China.
Hainan Medical College, 3 Xueyuan Road, Haikou 571199. China.
Curr Pharm Des. 2017;23(8):1142-1152. doi: 10.2174/1381612822666161014115724.
Cardiovascular disease still remains the primary cause of death worldwide and obesity is becoming recognized as one of the most critical contributing risk factors. The increased prevalence of obesity casts a cloud over the global health and the whole societies and will still be burdened in the future. Therefore, prevention and therapy of obesity is a beneficial strategy for the prevention of chronic cardiovascular disease. Numerous studies have demonstrated that gut microbiota takes part in human health and disease including obesity. Traditional herbs hold great potential to improve people's health and wellness, particularly in the area of chronic inflammatory diseases although the mechanisms of action remain poorly understood. Emerging explorations of gut microbiotaherb interactions provide a potential to revolutionize the way we view herbal therapeutics. This review summarizes the experimental studies performed on animals and humans regarding the gut microbiota-herb interactions targeting obesity. This review also discusses the opportunity of herbs with potent activities but low oral bioavailability conundrum for prevention and therapy for obesity and related cardiovascular disease.
心血管疾病仍然是全球主要的死亡原因，肥胖正被公认为是最关键的促成风险因素之一。肥胖患病率的上升给全球健康和整个社会蒙上了一层阴影，并且在未来仍将是一个负担。因此，预防和治疗肥胖是预防慢性心血管疾病的有益策略。大量研究表明，肠道微生物群参与包括肥胖在内的人类健康和疾病。传统草药具有改善人们健康的巨大潜力，特别是在慢性炎症性疾病领域，尽管其作用机制仍知之甚少。对肠道微生物群与草药相互作用的新探索为彻底改变我们看待草药治疗的方式提供了可能。本综述总结了针对肥胖的肠道微生物群与草药相互作用在动物和人类身上进行的实验研究。本综述还讨论了具有强大活性但口服生物利用度低的草药在预防和治疗肥胖及相关心血管疾病方面的机遇与难题。
